MOTS-c: A Research Overview of the Mitochondrial Peptide

Most peptides studied in a laboratory setting are encoded in the nuclear genome. MOTS-c is not. It is transcribed from a short open reading frame nested inside the mitochondrial 12S ribosomal RNA gene — a region of mtDNA that was, until relatively recently, assumed to code for nothing at all. That origin is the single most interesting thing about the molecule, and it is why MOTS-c has attracted attention well outside its immediate field: it is evidence that the mitochondrial genome, with its thirty-seven canonical genes, encodes signalling molecules that act on the nucleus.

This article summarises what the published literature reports about MOTS-c — its chemistry, the principal experimental findings, the human association data, and the handling and analytical considerations relevant to its use as a laboratory reference material. Everything described below refers to work published in cell culture, rodent models or human observational cohorts. Nothing here describes use in humans outside those studies.

Chemistry and genomic origin

MOTS-c — an acronym for mitochondrial open reading frame of the twelve S rRNA type-c — is a sixteen-residue peptide with the sequence Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg, written in single-letter code as MRWQEMGYIFYPRKLR. Its molecular weight is approximately 2,174.6 Da and it is commonly catalogued under CAS 627580-64-6.

Two features of that sequence matter practically. First, it is strongly basic: three arginine residues and one lysine give the peptide a high net positive charge at neutral pH, which influences its chromatographic behaviour and its interaction with glassware and plastics. Second, it contains two methionine residues, both of which are susceptible to oxidation to the sulfoxide. Methionine oxidation adds sixteen mass units per residue and is one of the more common degradation products seen in stored preparations of methionine-containing peptides, which is directly relevant to how a certificate of analysis for this compound should be read.

The peptide is translated from a 51-nucleotide open reading frame within the mitochondrial 12S rRNA gene. Because mitochondria use a genetic code that differs slightly from the nuclear code, and because the peptide is short, this reading frame went uncharacterised for decades. MOTS-c belongs to a small family of mitochondrial-derived peptides (MDPs) that also includes humanin and the SHLP series.

The 2015 characterisation paper

MOTS-c was described by Lee and colleagues in Cell Metabolism (2015), and that paper still defines the mechanistic framework applied to the peptide. Working in cultured cells and in mice, the authors reported that MOTS-c inhibits the folate cycle and, with it, the de novo purine biosynthesis pathway that draws on folate-derived one-carbon units. The consequence they measured was an accumulation of the purine intermediate AICAR — reported as a greater than twenty-fold increase in endogenous AICAR levels. AICAR is a well-characterised allosteric activator of AMP-activated protein kinase, and the paper reported corresponding AMPK activation in HEK293 cells and in mouse skeletal muscle.

That mechanism is worth stating carefully, because it is frequently compressed in secondary sources into "MOTS-c activates AMPK". The proposed sequence is indirect: inhibition of a metabolic pathway causes an intermediate to accumulate, and the intermediate activates the kinase. The same paper reported that MOTS-c administration in mice was associated with resistance to diet-induced obesity and to age-dependent and high-fat-diet-induced insulin resistance, and that AMPK activation was accompanied by increased expression of the downstream glucose transporter GLUT4 in skeletal muscle.

Retrograde signalling to the nucleus

Kim, Son, Benayoun and Lee extended the picture in Cell Metabolism (2018) by asking where the peptide goes under stress. Using glucose restriction, serum deprivation and oxidative stress in cell culture, they reported that MOTS-c translocates from the mitochondrial compartment to the nucleus, and that it does so quickly — on the order of thirty minutes. In the nucleus, the peptide was reported to associate with stress-responsive transcription factors and to regulate genes carrying antioxidant response elements (ARE), including through interaction with NFE2L2/Nrf2. The translocation was described as AMPK-dependent.

The significance of this result is conceptual rather than applied. It positions MOTS-c as a retrograde mitochondria-to-nucleus signal — a molecule by which the organelle reports its metabolic state to the nuclear genome — rather than simply as a circulating factor acting on cell-surface receptors. Whether the same translocation occurs at physiologically meaningful rates in intact tissue, as opposed to in stressed cultured cells, is not settled.

Exercise induction and physical performance in rodents

The most-cited recent work is Reynolds and colleagues in Nature Communications (2021), which examined MOTS-c in the context of exercise and ageing. The study reported improved physical performance in mice at three ages — 2, 12 and 22 months — following MOTS-c administration.

The specific measurements are instructive. In young outbred CD-1 mice given intraperitoneal MOTS-c for two weeks, treadmill running curves, total time on the treadmill and total distance run all increased significantly at the higher of two doses tested. A rotarod test in a separate cohort showed improved performance, but grip strength did not change, and Barnes maze testing showed no improvement in learning or memory — useful negative results, since they argue the treadmill effect is not simply a general increase in activity or arousal. In C57BL/6J mice on a high-fat diet, running performance and power output improved regardless of diet. Targeted metabolomics identified changes in glycolysis and the pentose phosphate pathway, and in amino acid metabolism, in skeletal muscle but not in liver — consistent with the tissue specificity reported in 2015. Notably, the performance effect did not correlate with body weight, which argues against it being a secondary consequence of reduced fat mass.

The same paper reported that intermittent administration begun late in life (23.5 months, three times weekly) increased physical capacity in aged mice, and — the observation that generated most of the coverage — that exercise induces endogenous MOTS-c expression in human skeletal muscle and in circulation.

Hyatt and colleagues (Physiological Reports, 2022) examined the same relationship from the training side. In rats, four to eight weeks of voluntary running increased MOTS-c protein in plantaris, medial gastrocnemius and tibialis anterior muscle by roughly 1.5- to 5-fold relative to sedentary controls, an elevation that persisted through four to six weeks of detraining. In untrained mice, a single 15 mg/kg dose was associated with a 12% increase in total running time and a 15% increase in distance during an acute exercise test. The authors also observed cytoplasm-to-nucleus translocation of MOTS-c protein following a 90-minute downhill running challenge, though in only two of six soleus muscles examined — a small n that the paper itself presents as preliminary.

Human genetic association data

The human evidence base for MOTS-c is almost entirely observational and genetic rather than interventional. It centres on a single nucleotide polymorphism, m.1382A>C (rs111033358), which lies within the MOTS-c reading frame and substitutes glutamine for lysine at position 14 — the K14Q variant. The C allele is essentially restricted to Northeast Asian populations.

Fuku and colleagues (Aging Cell, 2015) reported an association between this variant and exceptional longevity in a Japanese cohort, and proposed the mitokine as a candidate biological mechanism. Later work has complicated that reading. The K14Q variant has been characterised as having reduced biological activity relative to the wild-type peptide, and subsequent analyses have associated the C allele with altered body composition and elevated type 2 diabetes risk in Japanese men, with the association reported as strongest in sedentary individuals. Separate work has examined the variant in relation to muscle fibre composition and muscular performance, and a 2024 study in Biomedicines looked at K14Q in relation to sarcopenia and blood lipids in older Korean adults.

Taken together, these are population associations in specific ancestral groups. They are consistent with the peptide having a physiological role, but they do not establish causation, and the apparently opposing directions of the longevity and diabetes findings illustrate how much interpretive weight a single low-frequency variant is being asked to carry.

Laboratory handling

MOTS-c is supplied as a lyophilised white powder. Several properties follow from its composition rather than from generic peptide practice.

• Oxidation risk is elevated. Two methionine residues make the peptide more prone to oxidative modification than a comparable methionine-free sequence. Minimising headspace oxygen, light and elevated temperature is proportionately more important, and oxidised species are worth looking for specifically on a mass spectrum.
• Adsorption losses matter at low concentration. The high net positive charge promotes binding to glass and to some plastics. Dilute working solutions can lose material to container surfaces, which is a common source of unexplained potency variation in cell-culture experiments.
• Aliquot after reconstitution. Repeated freeze–thaw cycling degrades peptides generally; aliquoting avoids cycling a single vial.
• Lyophilised material is the stable form. Reconstituted solutions should not be assumed stable indefinitely, and storage temperature and time should be recorded alongside experimental results.

The underlying principles are covered in more detail in our guide to peptide storage and handling.

Analytical verification

Reversed-phase HPLC establishes chromatographic purity, and mass spectrometry confirms identity against the expected monoisotopic mass. For MOTS-c specifically, the mass spectrum deserves closer reading than usual: peaks at +16 and +32 Da relative to the parent mass indicate methionine sulfoxide formation on one or both methionines. Such species may not resolve cleanly from the parent peak by HPLC alone, so a purity figure quoted from a chromatogram does not by itself exclude oxidative degradation. Reading the full certificate of analysis, including the chromatogram and the raw spectrum rather than only the summary percentage, is the practical minimum; our guide to reading a peptide COA covers what to look for. Third-party analytical documentation for our catalogue is published on the Lab Results page.

What remains unresolved

The MOTS-c literature is young — the peptide was described just over a decade ago — and several fundamental questions are open. No receptor has been definitively identified, which leaves the mechanism by which extracellular MOTS-c enters cells incompletely explained. Circulating concentrations are difficult to measure reliably, and assay-to-assay disagreement in reported plasma levels is a recognised problem in the field. The relationship between endogenous, exercise-induced MOTS-c and exogenously administered peptide is not established; the two are routinely discussed as though interchangeable, and there is no strong evidence that they are. Above all, the performance and metabolic findings are rodent data. Human work to date is associative genetics, not intervention.

For laboratories working with MOTS-c as a reference compound, that combination — a well-defined molecule with an unusually clear genomic story and an unusually incomplete pharmacological one — is precisely what makes it a useful experimental subject.

Research use only. Not a medicine, supplement or therapeutic good. Not for human or veterinary consumption.